{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-051345","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2025-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.443756+00:00","generated_at":"2026-05-23T20:16:32.091545+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lexeo reports positive interim Phase 1/2 data for LX2006 in FA cardiomyopathy; 25% LVMI reduction","bullets":["Participants with abnormal LVMI at baseline achieved 25% mean reduction by 12 months or sooner.","High-dose cohort (Cohort 3) showed 115% mean increase in cardiac frataxin expression at 3 months.","LX2006 well tolerated; no Grade 3+ SAEs, no complement activation, no discontinuations.","FDA alignment on co-primary endpoints (LVMI >10% improvement, any frataxin increase) for registrational study.","Registrational study expected to initiate by early 2026; natural history study enrollment starts Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-051345","json":"https://secwatch.observer/filing/0000950170-25-051345.json","markdown":"https://secwatch.observer/filing/0000950170-25-051345.md","text":"https://secwatch.observer/filing/0000950170-25-051345.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017025051345/0000950170-25-051345-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017025051345/lxeo-20250407.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T20:16:32.091545+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}